Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., February 05, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 12, 2025 beginning at 2:00 p.m. Eastern Time.
A live webcast of the fireside chat will be accessible on the Events page under the News & Events heading of Quince's Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.
About Quince Therapeutics
Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205854544/en/
Contacts
Media & Investor Contact: Stacy RoughanQuince Therapeutics, Inc.Vice President, Corporate Communications & Investor Relationsir@quincetx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Why Roku Stock Jumped 13% This Morning
Roku stock soared after announcing an exclusive advertising partnership with Amazon's ad-selling service. Advertisers will be able to reach 80% of U.S. connected TV households through Amazon's platform. Amazon stock moved slightly on the news, but Roku saw a far bigger boost. 10 stocks we like better than Roku › Shares of Roku (NASDAQ: ROKU) rose as much as 13.4% on Monday morning, dropping back to a 10% gain by noon ET. The media-streaming technology expert announced an advertising partnership with Amazon (NASDAQ: AMZN). The new deal gives advertisers access to Roku's media-playing platform through the Amazon DSP advertising platform. It's an exclusive partnership with deeper data access than Roku's existing ad-sales deals, making Amazon's service the easiest route to placing ads across all of Roku's original and third-party content services. The companies said that this combination grows the effective market reach for ad buyers while also placing more varied marketing messages in front of the consumer. Between Roku's media players and the Amazon Prime Video service, Amazon DSP now reaches 80% of American media households. Amazon stock also rose slightly on the news, but the partnership should make a bigger difference to Roku's business. The company now has direct ad placement deals with the three largest ad management platforms. After Monday's price jump, Roku's stock has gained 42% in 12 months. It still looks quite affordable at 2.8 times trailing sales, despite the company's habit of delivering year-over-year revenue growth of 15% or more in recent quarters. Before you buy stock in Roku, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roku wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Anders Bylund has positions in Amazon and Roku. The Motley Fool has positions in and recommends Amazon and Roku. The Motley Fool has a disclosure policy. Why Roku Stock Jumped 13% This Morning was originally published by The Motley Fool
Yahoo
43 minutes ago
- Yahoo
Why Sarepta Therapeutics (SRPT) Stock Is Down Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy. Elevidys. In response, the company temporarily halted shipments of Elevidys for patients who are unable to walk and paused an associated clinical trial. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Sarepta Therapeutics? Access our full analysis report here, it's free. Sarepta Therapeutics's shares are very volatile and have had 25 moves greater than 5% over the last year. But moves this big are rare even for Sarepta Therapeutics and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 3 months ago when the stock dropped 24.9% on the news that the company reported the death of a Duchenne muscular dystrophy patient following treatment with its gene therapy, ELEVIDYS. The patient reportedly suffered acute liver failure, a known risk of AAV-mediated gene therapies. However, Sarepta suggested that a recent cytomegalovirus (CMV) infection might have worsened the condition. Despite this, the company maintained that ELEVIDYS still had a favorable benefit-risk profile. It planned to update the prescribing information and inform regulators, clinical investigators, and prescribing physicians of the incident. Markets were likely reacting negatively due to concerns that the event could increase regulatory scrutiny, make doctors more hesitant to prescribe the therapy, or slow adoption overall. ELEVIDYS had been a big piece of Sarepta's growth story as it contributed more than 50% of sales in the Q4'2024 quarter. Any threat to its continued adoption could put pressure on the stock. Sarepta Therapeutics is down 84.1% since the beginning of the year, and at $19.70 per share, it is trading 88% below its 52-week high of $163.85 from June 2024. Investors who bought $1,000 worth of Sarepta Therapeutics's shares 5 years ago would now be looking at an investment worth $122.96. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
American Water 2024 Water Quality Reports Show Drinking Water Meets Quality Standards
CAMDEN, N.J., June 16, 2025--(BUSINESS WIRE)--American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., announced today that its 2024 Water Quality Reports across 24 states are available on its website. The company is proud to report that, once again, the drinking water provided to more than 14 million people meets or surpasses both state and federal water quality standards for all regulated substances, including lead. "American Water is proud to continually provide safe, clean and reliable drinking water and wastewater services to our customers because they deserve nothing less," said Cheryl Norton, EVP and Chief Operating Officer, American Water. "These reports are valuable resources to learn about drinking water standards and the vital work involved in the water treatment process to meet or surpass federal and local regulations." The 2024 annual water quality reports, also known as a "consumer confidence reports," detail the quality of water the company provides to its customers using data collected from water quality testing in its local systems between January and December 2024. It highlights the compounds detected in treated drinking water in comparison to the compliance standards established by the U.S. Environmental Protection Agency (EPA) and local public utility commissions. To enhance education and transparency, the reports also include results of tests conducted on certain unregulated compounds in areas where they are present. To learn more about American Water's commitment to infrastructure investment, water education, environmental stewardship, quality service and more, visit: About American WaterAmerican Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders. For more information, visit and join American Water on LinkedIn, Facebook, X and Instagram. View source version on Contacts Media ContactAlicia BarbieriDirector, Corporate Communications and External AffairsAmerican Water(856) Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
